MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

Core Viewpoint - MaxCyte, Inc. is set to release its financial results for Q3 2025 on November 5, 2025, after the U.S. market closes, followed by a conference call to discuss these results [1]. Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3]. - The company utilizes its Flow Electroporation technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3]. - With over 25 years of experience, MaxCyte aims to empower researchers globally to engineer diverse cell types and payloads, thereby accelerating the development of safe and effective treatments [3]. Investor Relations - Investors interested in the upcoming conference call must register online, with a recommendation to do so at least a day in advance [2]. - A live and archived webcast of the conference call will be available on the MaxCyte website [2].